Navigation Links
BiOptix Announces Additional $1.4M in Funding to Aid in Commercialization and Working Capital Needs
Date:8/13/2014

BOULDER, Colo., Aug. 13, 2014 /PRNewswire/ -- BiOptix announced today an additional $1.4M financing from existing investors.  The funds will be used to expand sales and marketing and ramp up manufacturing to meet growing customer demand. 

Rick Whitcomb, President and CEO of BiOptix, noted:  "This latest increase in capital shows that our investors are confident in our plan and our team, and that BiOptix is on a solid path to commercial success."  BiOptix continues to see opportunity in the label-free marketplace, which is looking for a high quality, high performance SPR instrument at a reasonable price. "We are making great inroads in the marketplace, and this infusion of capital will aid our efforts to reach as many scientific researchers as possible," commented Whitcomb.

Surface Plasmon Resonance (SPR) is an advanced and highly sensitive optical technology that measures refractive index changes on a sensor chip's gold surface due to a change in mass that occurs during a binding event. This change can be used to monitor biological interactions such as the concentration of target molecules, kinetic rates and affinity constants. BiOptix has developed and patented a novel ultra-sensitive detection platform known as Enhanced Surface Plasmon Resonance, or ESPR. Unlike traditional SPR, ESPR instrumentation from BiOptix marries the high sensitivity of SPR with the high stability and lower noise of common path interferometry.

About BiOptix

BiOptix Diagnostics is a privately held firm based in Boulder, Colorado, with leading investments from Boulder Ventures, Remeditex and Rusnano.  BiOptix has developed a new class of analytical biosensor instrumentation utilizing ESPR – Enhanced Surface Plasmon Resonance. BiOptix instrumentation allows researchers to study label-free protein-protein and protein-small molecule interaction—with high sensitivity and high throughput. Applications include: Protein-small molecule interactions, protein-protein kinetics, antibody affinities and epitope mapping, oligosaccharide characterization, nucleic acid (DNA-DNA or DNA-RNA) hybridization and biomolecule concentration measurements. Additional information about BiOptix and our products can be found at:  www.bioptix.com


'/>"/>
SOURCE BiOptix
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. BiOptix announces expansion of Innovators Program into Europe
2. BiOptix announces low cost Surface Plasmon Resonance Services for Colorado-based researchers
3. BiOptix to highlight new carbonic anhydrase data at IBCs Biopharmaceutical Development & Production Week
4. BiOptix announces expansion of Innovators Program at Molecular Med TRI-CON 2013
5. BiOptix Announces Fall 2012 Tradeshow and Symposia Schedule
6. Perrigo Company plc Announces Quarterly Dividend
7. Kindred Biosciences Announces Second Quarter 2014 Financial Results
8. Imprimis Pharmaceuticals Announces Second Quarter 2014 Financial Results and Provides Operational Update
9. WuXi PharmaTech Announces Second-Quarter 2014 Results
10. Nutrastar International Inc. Announces Second Quarter 2014 Results
11. Novogen Announces Results of General Meeting of Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)...  In conjunction with DURECT Corporation,s (Nasdaq: ... you are invited to listen to a conference call ... Tuesday, March 14, 2017 at 4:30 pm Eastern Time ... webcast of the presentation will be available by accessing ... Relations."  If you are unable to participate during the ...
(Date:2/24/2017)... Report analyzes the worldwide markets for Endodontic Supplies in US$ ... Canada , Japan , ... Latin America , and Rest of World. ... through 2022. Also, a six-year historic analysis is provided for ... and secondary research. Company profiles are primarily based on public ...
(Date:2/24/2017)... 23, 2017  This report analyzes the worldwide markets ... Products: Intermediates, Analytical, and Others. The ... Pharmaceuticals, and Agrochemicals. The report provides separate comprehensive analytics ... Europe , and Rest of World. Annual ... through 2022. Also, a six-year historic analysis is provided ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... 2017 , ... Only two months after the official release of The Private ... (France), XO Private has initiated a second print-run of its lavish luxury travel coffee ... across when open, weighs in at more than six kilos, retails at EUR 1,000 ...
(Date:2/24/2017)... ... February 24, 2017 , ... An in-depth computational analysis of ... of Pittsburgh points to eight genes that may explain why susceptibility to one of ... results of a study published today in the journal npj Schizophrenia. , “There ...
(Date:2/24/2017)... ... , ... The Smart Machine Age is here, and it’s disrupting everything. Not ... all jobs in the United States may be taken over by technology in the ... know-it-all who steamrolls over colleagues is drawing to a close. Success will belong to ...
(Date:2/24/2017)... ... February 24, 2017 , ... With millions of Americans and ... that we all are aware of our options and are empowered with strength ... the launch of its newest edition of "Vision and Hearing" in USA Today, ...
(Date:2/24/2017)... Melbourne, Australia (PRWEB) , ... February 24, 2017 , ... ... Press AU) offers Erik Schanssema ’s true account of his paramedic experiences. Schanssema ... post-traumatic stress disorder and his attempts to overcome them. , Schanssema, initially unsure ...
Breaking Medicine News(10 mins):